Bleeding diathesis: Difference between revisions
m (Bot: Removing from Primary care) |
|||
(10 intermediate revisions by 3 users not shown) | |||
Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{MJ}}, {{N.F}}, {{S.G.}} | {{CMG}}; {{AE}} {{MJ}}, {{N.F}}, {{S.G.}} | ||
{{SK}} Hypocoagulopathy; | {{SK}} Hypocoagulopathy; blood coagulation disorders; hemorrhagic diathesis; hemostasis abnormality; bleeding tendency | ||
== Overview == | == Overview == | ||
Bleeding diathesis is susceptibility to bleed due to [[Coagulopathy|coagulopathy disorders]] or platelets disorders. These diseases can occur due to a disorder of [[homeostasis]], localized process ([[tissue]] injury), or [[Medication|medications]]. Bleeding diathesis can be resulted from [[vessel wall]] injury, [[platelet]] disorders, and [[coagulation factor]] disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. [[Platelet]] disorders mostly have skin manifestations such as [[Petechia|petechiae]], and [[ecchymoses]]. In order to find the cause of hypo-[[coagulopathy]]; there are established laboratory tests, such as [[peripheral blood smear]], [[platelet]] count and [[platelet]] function analysis, [[coagulation factor]] deficiencies and inhibitors, [[fibrinolysis]] tests (eg. [[D-dimer]] level), [[bleeding time|bleeding time (BT)]], [[prothrombin time|prothrombin time (PT)]], [[Partial thromboplastin time|activated partial thromboplastin time (aPTT)]], [[thrombin time]] (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are [[Complete blood count|CBC]], [[PT]], [[Partial thromboplastin time|PTT]], [[Bleeding time|BT]], and [[Thrombin time|TT]]. | Bleeding diathesis is susceptibility to bleed due to [[Coagulopathy|coagulopathy disorders]] or [[platelets]] disorders. These diseases can occur due to a disorder of [[homeostasis]], localized process ([[tissue]] injury), or [[Medication|medications]]. Bleeding diathesis can be resulted from [[vessel wall]] injury, [[platelet]] disorders, and [[coagulation factor]] disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. [[Platelet]] disorders mostly have skin manifestations such as [[Petechia|petechiae]], and [[ecchymoses]]. In order to find the cause of hypo-[[coagulopathy]]; there are established laboratory tests, such as [[peripheral blood smear]], [[platelet]] count and [[platelet]] function analysis, [[coagulation factor]] deficiencies and inhibitors, [[fibrinolysis]] tests (eg. [[D-dimer]] level), [[bleeding time|bleeding time (BT)]], [[prothrombin time|prothrombin time (PT)]], [[Partial thromboplastin time|activated partial thromboplastin time (aPTT)]], [[thrombin time]] (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are [[Complete blood count|CBC]], [[PT]], [[Partial thromboplastin time|PTT]], [[Bleeding time|BT]], and [[Thrombin time|TT]]. | ||
== Classification == | == Classification == | ||
Line 22: | Line 23: | ||
{{familytree | | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | | | | | | D02 | | | D03 | | | | | | | |D01=Family history |D02=Normal plt count |D03=Low plt count | | | }} | {{familytree | | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | | | | | | D02 | | | D03 | | | | | | | |D01=Family history |D02=Normal plt count |D03=Low plt count | | | }} | ||
{{familytree | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|.| | | | | | | | |!| | | | | | | | | | | }} | {{familytree | | | | |,|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|.| | | | | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | E01 | | | | | | | | | | | | | | | | | | | E02 | | | | | | | E03 | | | | | | |E01=(+)<br>• Inherited coagulpathy |E02=(-)<br>• | {{familytree | | | | | E01 | | | | | | | | | | | | | | | | | | | E02 | | | | | | | E03 | | | | | | |E01=(+)<br>• Inherited coagulpathy |E02=(-)<br>• Acquired coagulopathy |E03=Functional Plt disorder | | |}} | ||
{{familytree | |,|-|-|-|+|-|-|-|.| | | | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|-|-|-|.| |!| | | }} | {{familytree | |,|-|-|-|+|-|-|-|.| | | | |,|-|-|-|v|-|-|-|v|-|-|-|+|-|-|-|-|-|-|.| |!| | | }} | ||
{{familytree | F01 | | F02 | | F03 | | | F04 | | F05 | | F06 | | F07 | | | | | F08 |!| | | |F01=↑Plt <br>• Hemophillia <br>• VWD <br>• Factor VIII or IX deficiency |F02=↑PT <br>• Factor VII | {{familytree | F01 | | F02 | | F03 | | | F04 | | F05 | | F06 | | F07 | | | | | F08 |!| | | |F01=↑Plt <br>• Hemophillia <br>• VWD <br>• Factor VIII or IX deficiency |F02=↑PT <br>• Factor VII deficiency |F03=↑PT&↑PTT <br>• Fibrinogen deficiency <br>• Factor II deficiency <br>• Factor V deficiency <br>• Factor X deficiency |F04=↑PTT <br>• Factor inhibitor <br>• Anti phospholipid Ab syndrome |F05=↑PT <br>• Factor inhibitor <br>• Vit K deficiency <br>• Liver disease |F06=↑PT&↑PTT <br>• Factor inhibit <br>• DIC <br>• Liver failure <br>• Late stage of Vit K deficiency |F07=↑ Afibrinogenemia <br>• Heparin inhibitor <br>• Direct thrombin inhibitor |F08=Abnormal solobity <br>• Factor XIII deficiency <br>• Cross-linkin inhibitor | | |}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | |,|-|^|-|.| | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | |,|-|^|-|.| | | | | | | | | }} | ||
Line 316: | Line 317: | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* AD inheritance | * AD inheritance | ||
* | * Abnormlities of platelet granule formation | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function | ||
Line 456: | Line 457: | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Impaired fibrin cross-linking or clot dissolution | * Impaired fibrin cross-linking or clot dissolution | ||
* Mild or severe bleeding | * Mild or severe bleeding depend on levels of functional fibrinogen | ||
* Variable age of onset | * Variable age of onset | ||
|- | |- | ||
Line 633: | Line 634: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]] | ! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]<ref>{{cite journal | vauthors = Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S |display-authors=etal | title = Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis; | volume = 41 | issue = 3 (41) | pages = 323–329 | date=2015}}</ref> | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" | | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" | | ||
* Sub unit A mutation disease (more common) | * Sub unit A mutation disease (more common) | ||
Line 654: | Line 655: | ||
* The severity of factor XIII deficiency bleeds can be different in different patients | * The severity of factor XIII deficiency bleeds can be different in different patients | ||
|- | |- | ||
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]] | ! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid26897598">{{cite journal |vauthors=Peyvandi F, Garagiola I, Young G |title=The past and future of haemophilia: diagnosis, treatments, and its complications |journal=Lancet |volume=388 |issue=10040 |pages=187–97 |date=July 2016 |pmid=26897598 |doi=10.1016/S0140-6736(15)01123-X |url=}}</ref> | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
Line 729: | Line 730: | ||
|- | |- | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases | ||
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]] | ! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="pmid580488">{{cite journal |vauthors=Siegal T, Seligsohn U, Aghai E, Modan M |title=Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases |journal=Thromb. Haemost. |volume=39 |issue=1 |pages=122–34 |date=February 1978 |pmid=580488 |doi= |url=}}</ref><ref name="pmid19222477">{{cite journal |vauthors=Levi M, Toh CH, Thachil J, Watson HG |title=Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology |journal=Br. J. Haematol. |volume=145 |issue=1 |pages=24–33 |date=April 2009 |pmid=19222477 |doi=10.1111/j.1365-2141.2009.07600.x |url=}}</ref><ref name="pmid18066597">{{cite journal |vauthors=Ghosh K, Shetty S |title=Blood coagulation in falciparum malaria--a review |journal=Parasitol. Res. |volume=102 |issue=4 |pages=571–6 |date=March 2008 |pmid=18066597 |doi=10.1007/s00436-007-0832-0 |url=}}</ref><ref name="pmid5804882">{{cite journal |vauthors=Siegal T, Seligsohn U, Aghai E, Modan M |title=Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases |journal=Thromb. Haemost. |volume=39 |issue=1 |pages=122–34 |date=February 1978 |pmid=580488 |doi= |url=}}</ref><ref name="pmid1531791">{{cite journal |vauthors=Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P |title=Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies |journal=Chest |volume=101 |issue=3 |pages=816–23 |date=March 1992 |pmid=1531791 |doi= |url=}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* [[Trauma]] | * [[Trauma]] | ||
Line 751: | Line 752: | ||
| align="center" style="background:#F5F5F5;" |− | | align="center" style="background:#F5F5F5;" |− | ||
|- | |- | ||
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]] | ! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]<ref name="pmid165052572">{{cite journal| author=Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG| title=Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. | journal=Arch Intern Med | year= 2006 | volume= 166 | issue= 4 | pages= 391-7 | pmid=16505257 | doi=10.1001/.391 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16505257 }}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Bleeding after trauma | * Bleeding after trauma | ||
Line 853: | Line 854: | ||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Emergency medicine]] |
Latest revision as of 20:38, 29 July 2020
Bleeding diathesis main page |
|
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Nazia Fuad M.D., Sogand Goudarzi, MD [3]
Synonyms and keywords: Hypocoagulopathy; blood coagulation disorders; hemorrhagic diathesis; hemostasis abnormality; bleeding tendency
Overview
Bleeding diathesis is susceptibility to bleed due to coagulopathy disorders or platelets disorders. These diseases can occur due to a disorder of homeostasis, localized process (tissue injury), or medications. Bleeding diathesis can be resulted from vessel wall injury, platelet disorders, and coagulation factor disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. Platelet disorders mostly have skin manifestations such as petechiae, and ecchymoses. In order to find the cause of hypo-coagulopathy; there are established laboratory tests, such as peripheral blood smear, platelet count and platelet function analysis, coagulation factor deficiencies and inhibitors, fibrinolysis tests (eg. D-dimer level), bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are CBC, PT, PTT, BT, and TT.
Classification
Disorders of hemostasis can be classified into two main categories: platelet disorders, and disorders of coagulation. Each category can be further classified as bellow:
Abnormal hemostasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Patient history-sign & symptom: deep soft tissue & mucocutaneus bleeding • Screen test CBC-Plt-PT&PTT-BT-TT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hx of deep soft tissue bleeding | Hx of mucocotaneus bleeding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coagulopathy | Plt disorder | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Family history | Normal plt count | Low plt count | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(+) • Inherited coagulpathy | (-) • Acquired coagulopathy | Functional Plt disorder | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
↑Plt • Hemophillia • VWD • Factor VIII or IX deficiency | ↑PT • Factor VII deficiency | ↑PT&↑PTT • Fibrinogen deficiency • Factor II deficiency • Factor V deficiency • Factor X deficiency | ↑PTT • Factor inhibitor • Anti phospholipid Ab syndrome | ↑PT • Factor inhibitor • Vit K deficiency • Liver disease | ↑PT&↑PTT • Factor inhibit • DIC • Liver failure • Late stage of Vit K deficiency | ↑ Afibrinogenemia • Heparin inhibitor • Direct thrombin inhibitor | Abnormal solobity • Factor XIII deficiency • Cross-linkin inhibitor | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Not corrected with mixing with NL plasma | HX(+) | HX(-) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Factor inhibitors • Lupus anti coagulant • DIC • Heparin or direct thrombin inhibitors | Congenital | Acquired | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differentiating Bleeding Disorders from Other Diseases
Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.
These features have discussed in the below table:
Category | Subcategory | Disease | History | Clinical manifestation | Laboratory testing | Comments | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | ||||||
Platelet disorders | Thrombocytopenia | Infection-Induced thrombocytopenia[1] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |
Medication-Induced Thrombocytopenia[2] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | Most important part of treatment is discontinuing of the medication. | |||
Heparin-Induced thrombocytopenia[3] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | ↑ | For more information click here: Heparin-induced thrombocytopenia. | |||
Immune Thrombocytopenic Purpura[4] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Inherited Thrombocytopenia[5] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Thrombotic Thrombocytopenic Purpura[6] | History of:
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Hemolytic Uremic Syndrome[7] | History of: | + | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Thromobcytosis | Iron deficiency anemia
Inflammatory diseases |
− | − | − | − | ± | ± | ↑ | Nl or ↑ | Nl | Nl | Nl | − | |||
Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | Glanzmann’s thrombasthenia |
|
+ | + | + | + | − | Rare | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |
Bernard-Soulier syndrome |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |||
Wiskott-Aldrich syndrome |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl | ||||
Platelet storage pool disorder: |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |||
Acquired Disorders of Platelet Function |
|
+ | + | + | + | ± | ± | Nl or ↓ | ↑ | Nl | Nl | Nl | − | |||
Von Willebrand Disease |
|
+ | + | + | + | ± | ± | ↑ | Nl | ↑ | ↑ | Nl | See the table below for the details about different types. | |||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Vessel wall disorders | Metabolic and Inflammatory Disorders |
|
|
− | + | + | ± | − | − | Nl | Nl or ↑ | Nl | Nl | Nl | − | |
Inherited Disorders of the Vessel Wall |
|
− | + | + | ± | − | − | Nl | Nl or ↑ | Nl | Nl | Nl | − | |||
Coagulation factor disorders | Fibrinogen deficiency |
Different types of the fibrinogen disorders: |
|
− | − | + | + | ± | + | Nl | ↑ | ↑ | ↑ | ↑ |
| |
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Prothrombin deficiency |
|
− | + | + | + | + | + | Nl | Nl | ↑ | ↑ | ↑ | − | |||
Factor V deficiency |
|
− | − | + | + | + | + | Nl | ↑ | ↑ | ↑ | Nl |
| |||
Factor VII deficiency |
|
+ | + | + | Nl | ↑ | Nl | Nl |
| |||||||
Factor X deficiency |
|
+ | + | + | + | + | Nl | Nl | ↑ | ↑ | Nl | − | ||||
Factor XII deficiency |
|
− | − | − | − | − | Nl | Nl | Nl | ↑ | Nl | |||||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
High molecular weight kininogen (HMWK) deficiency |
|
− | − | − | − | − | Nl | Nl | Nl | ↑ | Nl | |||||
Prekallikrein deficiency |
|
− | − | − | − | − | Nl | Nl | Nl | ↑ | Nl | |||||
Factor XIII deficiency[9] |
|
|
± | ± | ± | ± | ± | ± | Nl | Nl | Nl or ↑ | Nl | Nl |
| ||
Hemophilia[10] | Type A deficiency |
|
− | − | − | + | + | + | Nl | Nl | Nl | ↑ | Nl | − | ||
Type B deficiency |
|
− | − | − | + | + | + | Nl | Nl | Nl | ↑ | Nl | − | |||
Type C deficiency |
|
− | − | − | + | Rare | Rare | Nl | Nl | Nl | ↑ | Nl | − | |||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Rare diseases | Disseminated Intravascular Coagulation[11][12][13][14][15] |
|
+ | + | + | + | + | + | ↓ | ↑ | ↑ | ↑ | Nl | − | ||
Vitamin K Deficiency[16] |
|
+ | − | + | + | + | + | Nl | ↑ | ↑ | Nl or mildly prolonged | Nl | − |
Different types of Von-Willebrand diseases
Type of VWD | Type of factor deficiency | Prevalence | Inheritance pattern | Clinical manifestations | VWF activity | RIPA | Factor VIII | |
---|---|---|---|---|---|---|---|---|
Type 1 | Quantitative/ partial | 60-70% | AD |
|
↓ | ↓ | ↓ | |
Type 2 | 2A | Qualitative | 10% | AD/AR |
|
↓ | ↓ | N or ↓ |
2B | Qualitative | 5% | AD |
|
↓ | ↑ | N or ↓ | |
2M | Qualitative | <1% | AD/AR |
|
↓ | ↓ | N or ↓ | |
2N | Qualitative | <1% | AR |
|
N | N | ↓ | |
Type 3 | Complete deficiency | 1-2% | AR |
|
Absent | ↓ | Low, 1-10% |
For more information on Von Willebrand disease, click here.
References
- ↑ Herbinger, K.-H.; Schunk, M.; Nothdurft, H. D.; von Sonnenburg, F.; Löscher, T.; Bretzel, G. (2012). "Comparative study on infection-induced thrombocytopenia among returned travellers". Infection. 40 (4): 373–379. doi:10.1007/s15010-012-0242-9. ISSN 0300-8126.
- ↑ Elting, Linda S.; Cantor, Scott B.; Martin, Charles G.; Hamblin, Lois; Kurtin, Danna; Rivera, Edgardo; Vadhan-Raj, Saroj; Benjamin, Robert S. (2003). "Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors". Cancer. 97 (6): 1541–1550. doi:10.1002/cncr.11195. ISSN 0008-543X.
- ↑ Miller, Penny L. (2003). "Heparin-induced Thrombocytopenia Recognition and Treatment". AORN Journal. 78 (1): 79–89. doi:10.1016/S0001-2092(06)61348-3. ISSN 0001-2092.
- ↑ Curtis, Brian R.; Kaliszewski, James; Marques, Marisa B.; Saif, M. Wasif; Nabelle, Lisle; Blank, Jules; McFarland, Janice G.; Aster, Richard H. (2006). "Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin". American Journal of Hematology. 81 (3): 199–201. doi:10.1002/ajh.20516. ISSN 0361-8609.
- ↑ Drachman, J. G. (2004). "Inherited thrombocytopenia: when a low platelet count does not mean ITP". Blood. 103 (2): 390–398. doi:10.1182/blood-2003-05-1742. ISSN 0006-4971.
- ↑ George, James N. (2006). "Thrombotic Thrombocytopenic Purpura". New England Journal of Medicine. 354 (18): 1927–1935. doi:10.1056/NEJMcp053024. ISSN 0028-4793.
- ↑ Noris, M. (2005). "Hemolytic Uremic Syndrome". Journal of the American Society of Nephrology. 16 (4): 1035–1050. doi:10.1681/ASN.2004100861. ISSN 1046-6673.
- ↑
- ↑ Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, et al. (2015). "Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis;". 41 (3 (41)): 323–329.
- ↑ Peyvandi F, Garagiola I, Young G (July 2016). "The past and future of haemophilia: diagnosis, treatments, and its complications". Lancet. 388 (10040): 187–97. doi:10.1016/S0140-6736(15)01123-X. PMID 26897598.
- ↑ Siegal T, Seligsohn U, Aghai E, Modan M (February 1978). "Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases". Thromb. Haemost. 39 (1): 122–34. PMID 580488.
- ↑ Levi M, Toh CH, Thachil J, Watson HG (April 2009). "Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology". Br. J. Haematol. 145 (1): 24–33. doi:10.1111/j.1365-2141.2009.07600.x. PMID 19222477.
- ↑ Ghosh K, Shetty S (March 2008). "Blood coagulation in falciparum malaria--a review". Parasitol. Res. 102 (4): 571–6. doi:10.1007/s00436-007-0832-0. PMID 18066597.
- ↑ Siegal T, Seligsohn U, Aghai E, Modan M (February 1978). "Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases". Thromb. Haemost. 39 (1): 122–34. PMID 580488.
- ↑ Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (March 1992). "Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies". Chest. 101 (3): 816–23. PMID 1531791.
- ↑ Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG (2006). "Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis". Arch Intern Med. 166 (4): 391–7. doi:10.1001/.391. PMID 16505257.